(3S,4R,5S)-2-[6-amino-2-(1-pentylpyrazol-4-yl)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: (3S,4R,5S)-2-[6-amino-2-(1-pentylpyrazol-4-yl)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
• 化学式: C₁₈H₂₅N₇O₄
• 分子量: 403.4
• InChiKey: SZQIRVBJFJWUEK-HEACJYEFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  157
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• COMBINATIONS OF A RATE CONTROL AGENT AND AN A-2-ALPHA RECEPTOR ANTAGONIST FOR USE IN MULTIDETECTOR COMPUTED TOMOGRAPHY METHODS
  申请人：Gilead Sciences, Inc.

  公开号：EP2344145A1

  公开（公告）日：2011-07-20
• Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia
  申请人：Belardinelli Luiz

  公开号：US20070299089A1

  公开（公告）日：2007-12-27

  Methods for treating ischemia in mammals with one or more compounds that are agonists of mammalian adenosine A 2A receptors.
• Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease
  申请人：Lieu Hsiao D.

  公开号：US20080170990A1

  公开（公告）日：2008-07-17

  The present application discloses methods for myocardial imaging in human patients having a history of pulmonary disease such as asthma, bronchospasm, chronic obstructive pulmonary disease, pulmonary fibrosis, pulmonary inflammation, or pulmonary hypertension, comprising administrating doses of one or more A 2A adenosine receptor agonists to a mammal undergoing myocardial imaging and detecting and/or diagnosing myocardial dysfunction.
• Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods
  申请人：Lieu Hsiao

  公开号：US20080213165A1

  公开（公告）日：2008-09-04

  The present application discloses methods and compositions for increasing patient tolerability during myocardial imaging comprising the administration of doses of caffeine and one or more adenosine A 2A receptor agonists to a mammal undergoing myocardial imaging.
• Myocardial Perfusion Imaging
  申请人：Lieu Hsiao D.

  公开号：US20080267861A1

  公开（公告）日：2008-10-30

  This invention relates to methods for performing myocardial perfusion imaging for diagnosing and characterizing coronary artery disease using an intravenous (IV) bolus injection of regadenoson while the patient is undergoing sub-maximal exercise.